Print Page
Community Search
2018 Tamiflu Suspension Shortage

APA has received calls regarding the shortage of the suspension for Tamiflu. After conversations with the State Employee Insurance Board and Medicaid we want to make sure you are aware of the following.

State Employee Insurance Board

Due to the shortage of the suspension, Prime Therapeutics has removed compound restrictions to allow pharmacies to use the capsules to compound the suspension.  Please see information below provided by the State Employees’ Insurance Board:

You should direct any questions you may have regarding submitting claims directly to Prime Therapeutics Pharmacy Help Desk at 1-800-216-9920.


Medicaid

The brand Tamiflu is preferred so claims will pay at the brand rate. 

Although not relevant to Tamiflu, we wanted to remind you that Alabama Medicaid pharmacy providers may utilize DAW 8 in cases where the generic product is not in stock: 

8=Substitution Allowed‐Generic Drug Not Available in Marketplace‐This value is used when the prescriber has indicated, in a manner specified by prevailing law, that generic substitution is permitted and the brand product is dispensed since the generic is not currently manufactured, distributed, or is temporarily unavailable.

This information is listed on the website:  http://www.medicaid.alabama.gov/documents/4.0_Programs/4.3_Pharmacy-DME/4.3.2_Billing_Policy_Info/4.3.2_Appropriate_Utilization_DAW_Codes_10-3-12.pdf


Sign In


Latest News
APA CALENDAR

8/25/2018
2018 APhA Pharmacy-Based Immunization Delivery Training Program

8/25/2018
2018 Immunization Refresher Course

 

HOT TOPICS

Report from the Nominations Committee

House of Delegates Meeting, June 12, 2018 Point Clear, Ala.


Journal CE Articles NEW Articles & Online Quizzes!